TABLE 1.
Cohort Demographics Including Selected Recipient, Donor, and Transplant Characteristics (n = 1023)
| NASH Group (n = 207) | Non-NASH Group (n = 816) | P Value | |
|---|---|---|---|
| Age at transplant, years | 68.0 (66.4–70.0) | 67.3 (66.0–69.0) | 0.04 |
| Sex, female | 98 (47.3) | 268 (32.8) | <0.001 |
| Race | <0.001 | ||
| White | 162 (78.3) | 555 (68.0) | |
| Black | 1 (0.5) | 65 (8.0) | |
| Hispanic/Latino | 25 (12.1) | 75 (9.2) | |
| Asian | 7 (3.4) | 84 (10.3) | |
| Other | 12 (5.8) | 37 (4.5) | |
| HCC | 78 (37.7) | 464 (56.9) | <0.001 |
| Ascites | 167 (80.7) | 516 (63.3) | <0.001 |
| Hepatic encephalopathy | No 132 (64.1) | 407 (49.9) | <0.001 |
| History of variceal bleed | 60 (29.0) | 162 (19.9) | 0.006 |
| TIPS | 50 (24.2) | 65 (8.0) | <0.001 |
| Spontaneous bacterial peritonitis | 36 (17.4) | 90 (11.0) | 0.02 |
| Suspected hepatorenal syndrome | 49 (23.7) | 148 (18.1) | 0.09 |
| Portal vein thrombosis | 31 (15.0) | 99 (12.1) | 0.33 |
| Allocation (UNOS) MELD-Na | 25 (19–32) | 25 (16–32) | 0.38 |
| Laboratory MELD-Na | 21 (16–29) | 18 (12–26) | <0.001 |
| Exception points | 64 (30.9) | 380 (46.6) | <0.001 |
| Medical history | |||
| MI | 11 (5.3) | 43 (5.3) | 0.99 |
| Congestive heart failure | 18 (8.7) | 47 (5.8) | 0.17 |
| Peripheral vascular disease | 8 (3.9) | 39 (4.8) | 0.71 |
| Cerebrovascular disease | 16 (7.7) | 35 (4.3) | 0.07 |
| Chronic pulmonary disease | 23 (11.1) | 93 (11.4) | 0.99 |
| Diabetes without chronic complications | 121 (58.5) | 207 (25.4) | <0.001 |
| Diabetes with chronic complications | 23 (11.1) | 43 (5.3) | 0.004 |
| Moderate-to-severe renal disease* | 92 (44.4) | 295 (36.2) | 0.04 |
| Charlson comorbidity score | 8 (6–9) | 7 (6–8) | <0.001 |
| Hypertension | 136 (66.3) | 430 (54.0) | 0.002 |
| Hyperlipidemia | 95 (46.3) | 188 (23.8) | <0.001 |
| Atrial fibrillation | 15 (7.4) | 63 (7.9) | 0.90 |
| Deep vein thrombosis | 8 (3.9) | 31 (3.9) | 0.99 |
| CABG | 21 (10.3) | 19 (2.4) | 0.03 |
| Any CAD (history of PCI or CABG, or CAD seen on CTCA/Left heart catheterization) | 76 (36.7) | 168 (20.6) | <0.001 |
| CAR-OLT score | 40 (32–49) | 34 (27–40) | <0.001 |
| Donor and transplant variables | |||
| Donor age, years | 49.0 (34.0–61.0) | 45.0 (29.0–57.3) | 0.01 |
| DCD | 19 (9.2) | 55 (6.8) | 0.30 |
| Living donor LT | 24 (11.6) | 55 (6.7) | 0.03 |
| SLKT | 16 (7.7) | 71 (8.7) | 0.76 |
| DRI | 1.79 (1.43–2.03) | 1.61 (1.30–1.95) | 0.004 |
| Center variables | |||
| Transplant center volume | 0.97 | ||
| <50/year | 5 (2.4) | 20 (2.5) | |
| 50–100/year | 85 (41.1) | 327 (40.1) | |
| >100/year | 117 (56.5) | 469 (57.5) | |
NOTE: Data are given as median (IQR) or n (%).
*
Moderate-to-severe renal disease is defined by clinical assessment and includes chronic kidney disease, acute kidney injury, and hepatorenal syndrome.